title: In vivo behavior of MIL-100 nanoparticles at early times after intravenous administration.
abstract: Metal-organic frameworks have shown interesting features for biomedical applications, such as drug delivery and imaging agents. The benchmarked mesoporous iron(III) trimesate MIL-100 MOF nanocarrier combines progressive release of high drug cargoes with absence of visible in vivo toxicity. Although in a previous study pharmacokinetics and biodistribution of MIL-100 nanoparticles were evaluated in the long term (from 24h to 1 month), the crucial times for drug targeting and delivery applications are shorter (up to 24h). Thus, this work aims to study the blood circulating profile and organ accumulation of MIL-100 nanocarrier at early times after administration. For this purpose, after intravenous administration to rats, both constitutive components of MIL-100 (trimesate and iron) were quantified by high performance liquid chromatography and a spectrophotometric method, respectively. The pharmacokinetic profile suggested that the nanoparticles act as a depot in the blood stream during the first hours before being cleared. Accumulation took mainly place in the liver and, in some extent, in the spleen. Nevertheless, histological studies demonstrated the absence of morphological alterations due to the presence of the particles in these organs. Liver function was however slightly altered as reflected by the increased plasma aspartate aminotransferase concentrations. Finally trimesate was progressively eliminated in urine.
authors: Institut Lavoisier, Université de Versailles St Quentin, UMR CNRS 8180, 45 avenue des Etats-Unis, 78035 Versailles, France.
authors: T
authors: T
authors: Simon-Yarza
authors: Institut Lavoisier, Université de Versailles St Quentin, UMR CNRS 8180, 45 avenue des Etats-Unis, 78035 Versailles, France.
authors: T
authors: T
authors: Baati
authors: Laboratoire de Biochimie et de Toxicologie, CHU de Monastir, Tunisie.
authors: F
authors: F
authors: Neffati
authors: Service d'Anatomie et de Cytologie pathologiques, CHU Monastir, Tunisie.
authors: L
authors: L
authors: Njim
authors: Institut Galien, Université Paris-Sud, UMR CNRS 8612, Faculté de Pharmacie, 5 rue Jean-Baptiste Clément, F-92296 Châtenay-Malabry, France.
authors: P
authors: P
authors: Couvreur
authors: Institut Lavoisier, Université de Versailles St Quentin, UMR CNRS 8180, 45 avenue des Etats-Unis, 78035 Versailles, France.
authors: C
authors: C
authors: Serre
authors: Institut Galien, Université Paris-Sud, UMR CNRS 8612, Faculté de Pharmacie, 5 rue Jean-Baptiste Clément, F-92296 Châtenay-Malabry, France.
authors: R
authors: R
authors: Gref
authors: Laboratoire de Biochimie et de Toxicologie, CHU de Monastir, Tunisie.
authors: M Fadhel
authors: MF
authors: Najjar
authors: Service d'Anatomie et de Cytologie pathologiques, CHU Monastir, Tunisie.
authors: A
authors: A
authors: Zakhama
authors: Institut Lavoisier, Université de Versailles St Quentin, UMR CNRS 8180, 45 avenue des Etats-Unis, 78035 Versailles, France; IMDEA Energy, Avda, Ramón de la Sagra 3, 28935 Móstoles, Madrid, Spain. Electronic address: patricia.horcajada@imdea.org.
authors: P
authors: P
authors: Horcajada
mesh_terms: D061605:Administration, Intravenous; D000818:Animals; D001682:Biological Availability; D005260:Female; D058085:Iron Compounds / Q000008:administration & dosage* / Q000378:metabolism*; D053758:Nanoparticles / Q000008:administration & dosage* / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors
chemical_list: D058085:Iron Compounds
keywords: Biodistribution; Coordination polymers; Drug delivery system pharmacokinetics; Iron (PubChem CID: 23925); Metal-organic frameworks; Trimesic acid (PubChem CID: 11138)